Specifically, we could robustly predict responders and non-responders using the expression levels of network-based biomarkers in more than 700 patient samples, covering melanoma, metastatic gastric and bladder cancer patients treated with ICIs targeting the PD1/PD-L1 axis. This evidence concerns the gene CD274 and urinary bladder cancer.